These data highlight CXCR3 as a key receptor whose expression in specific immune cell types, immunosuppressive or effector, can regulate both the type and intensity of the anti-tumor immune response, shaping the tumor outcome and potentially determining the efficacy of therapeutic interventions. Here, CXCR3 is linked to neoplasm.